Current research has identified the metabolic and intestinal effects of SCFA in experimental models and humans. Ample physiologic rationale has come forth to justify controlled studies of the administration of SCFA in selected patients with intestinal dysfunction.
No takes yet. Share an insight, caveat, or question.
Rombeau et al. (1990) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: